Investigating how epigenetic aging affects racial disparities in early-onset prostate cancer
Epigenetic aging as a driver of racial disparities in early onset prostate cancer
This study is looking at how biological aging might be linked to the higher rates of early-onset prostate cancer in African American men, and it hopes to find ways to help reduce this risk by comparing their aging markers to those of European American men.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10983413 on NIH RePORTER |
What this research studies
This research focuses on understanding the link between epigenetic aging and the higher rates of early-onset prostate cancer in African American men. It examines how ancestry and race may influence biological aging markers, specifically ribosomal DNA methylation, which could explain the increased risk of prostate cancer in this population. By comparing the epigenetic age of African American prostate cancer patients to that of European American patients, the study aims to identify factors contributing to these disparities. The findings could lead to targeted interventions to reduce the risk of early-onset prostate cancer in African American men.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American men diagnosed with early-onset prostate cancer.
Not a fit: Patients who do not have prostate cancer or are not of African descent may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved screening and prevention strategies for early-onset prostate cancer in African American men.
How similar studies have performed: Previous research has indicated that epigenetic markers can provide insights into cancer risk, suggesting potential for success in this novel approach.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Woloszynska-Read, Anna — Roswell Park Cancer Institute Corp
- Study coordinator: Woloszynska-Read, Anna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.